A new therapeutic approach for bone metastasis in colorectal cancer: intratumoral melittin

Autor(es)

Mackson Martins Rocha ^[1] ; Isabela Dariva ^[2] ; Gabriela Comelli Zornoff ^[3] ; Giovanna Sanches De Laurentis ^[4] ; Giulia Carli Mendes ^[5] ; Maycon Giovani Santana ^[6] ; Guilherme Chohfi de Miguel ^[7] ; Rui Seabra Ferreira Junior ^[8] ; Juliana Mozer Sciani ^[9] ; Denise Gonçalves Priolli ^[10]

Afiliação do(s) autor(es)

^[1] São Francisco University. Multidisciplinary Laboratory, Postgraduate Program in Health Sciences - Brasil

^[2] São Francisco University. Medical School - Brasil

^[3] São Francisco University. Medical School - Brasil

^[4] São Francisco University. Medical School - Brasil

^[5] São Francisco University. Medical School - Brasil

^[6] São Francisco University. Nursing School - Brasil

^[7] São Francisco University. Medical School - Brasil

^[8] São Paulo State University (UNESP). Center for the Studies of Venoms and Venomous Animals (CEVAP) - Brasil

^[9] São Francisco University. Multidisciplinary Laboratory, Postgraduate Program in Health Sciences - Brasil

^[10] São Francisco University. Multidisciplinary Laboratory, Postgraduate Program in Health Sciences - Brasil

• Tipo de documento: Artigo Científico
• Fonte: Journal of Venomous Animals and Toxins including Tropical Diseases; v. 28, 2022-03-14.

Resumo

Abstract Background: Melittin has shown antiproliferative effects on tumor cells. Therefore, it comprises a valuable compound for studies on cancer treatment. To the best of our knowledge, no studies have reported melittin effects on bone metastasis. Herein, we propose an approach based on intrametastatic melittin injection to treat bone metastases in colorectal cancer. Methods: Following the characterization of melittin and antiproliferative tests in vitro, a single dose was injected through intrametastatic route into the mouse bone metastasis model. Following treatment, metastasis growth was evaluated. Results: A single dose of melittin was able to inhibit metastasis growth. Histological analysis showed necrosis and inflammatory processes in melittin-treated metastasis. Except by mild weight loss, no other systemic effects were observed. Conclusion: Our data suggest that melittin might be a promising agent for the future development of treatment strategies aiming to reduce the bone metastasis skeletal-related impact in colorectal cancer patients with bone metastasis. (AU)

• Processo FAPESP: 18/21471-5 - Vasoibina: potencial alvo para inibição de angiogênese no câncer colorretal
• Beneficiário: Denise Gonçalves Priolli
• Modalidade de apoio: Auxílio à Pesquisa - Regular